Kiniksa Pharmaceuticals
KNSA
204 hedge funds and large institutions have $1.59B invested in Kiniksa Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 60 increasing their positions, 70 reducing their positions, and 32 closing their positions.
530% more call options, than puts
Call options by funds: $24.1M | Put options by funds: $3.82M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
47% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 32
44% more capital invested
Capital invested by funds: $1.1B → $1.59B (+$483M)
8% more funds holding
Funds holding: 189 → 204 (+15)
0.19% less ownership
Funds ownership: 94.14% → 93.95% (-0.19%)
14% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 70
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$12.9M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$12.8M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$11.4M |
| 4 |
D.E. Shaw & Co
New York
|
+$11.1M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$14.9M |
| 2 |
Squarepoint
New York
|
-$10.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.15M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$8.97M |
| 5 |
BlackRock
New York
|
-$7.97M |
KNSA Hedge Fund Activity: Q3 2025 in Review
204 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2025, worth a combined $1.59B — up 44% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new KNSA positions and 32 closed out — a net gain of 15 holders — while 60 added to existing stakes and 70 trimmed.
The largest buyer was Nomura Holdings, opening a new position worth an estimated $12.9M. The largest seller was Braidwell, cutting an estimated $14.9M.
- 204 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2025, up from 189 in Q2 2025.
- Funds reported $1.59B of Kiniksa Pharmaceuticals stock for Q3 2025, up 44% quarter-over-quarter.
- 47 funds opened new Kiniksa Pharmaceuticals positions in Q3 2025 and 32 closed out, a net change of +15 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2025 was Nomura Holdings, an estimated $12.9M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2025 was Braidwell, an estimated $14.9M sold.
Based on aggregated 13F filings for Q3 2025.